Effects of an Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer |
Kim, Hyun Jung
(Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Woo Sung (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) Kwon, Do Hoon (Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine) Cho, Young Hyun (Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine) Choi, Chang-Min (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) |
1 | Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 : 2483-2491, 2006 DOI |
2 | Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E : Gefitinib in patients with brain metastases from non-small-cell lung cancer : a prospective trial. Ann Oncol 15 : 1042-1047, 2004 DOI |
3 | Clarke JL, Pao W, Wu N, Miller VA, Lassman AB : High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99 : 283-286, 2010 DOI |
4 | Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. : "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13 : 1364-1369, 2011 DOI |
5 | Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. : Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16 : 5873-5882, 2010 DOI |
6 | Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, et al. : Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46 : 255-261, 2004 DOI |
7 | Kim HS, Koh EJ, Choi HY : Multiple gamma knife radiosurgery for multiple metachronous brain metastases associated with lung cancer : survival time. J Korean Neurosurg Soc 52 : 334-338, 2012 DOI |
8 | Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS : Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 50 : 265-269, 2005 DOI |
9 | Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 29 : 134-141, 2011 |
10 | Kuiper JL, Smit EF : High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well. Lung Cancer 80 : 102-105, 2013 DOI |
11 | Langer CJ, Mehta MP : Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 : 6207-6219, 2005 DOI |
12 | Ma S, Xu Y, Deng Q, Yu X : Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65 : 198-203, 2009 DOI |
13 | Minniti G, Esposito V, Clarke E, Scaringi C, Bozzao A, Lanzetta G, et al. : Stereotactic radiosurgery in elderly patients with brain metastases. J Neurooncol 111 : 319-325, 2013 DOI |
14 | Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. : Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 : 2513-2520, 2005 DOI |
15 | Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, et al. : Gefitinib in patients with brain metastases from non-small-cell lung cancer : review of 15 clinical cases. Clin Lung Cancer 6 : 123-128, 2004 DOI |
16 | National Comprehensive Cancer Network I : National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Non-Small Cell lung cancer. Washington DC : National Comprehensive Cancer Network, 2014 |
17 | Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD : Radiosurgery for non-small cell lung carcinoma metastatic to the brain : long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97 : 1276-1281, 2002 DOI |
18 | Park BJ, Lim YJ, Kim TS, Rhee BA, Leem W, Kim GK : Brain metastasis from lung cancer-treatment and prognosis-. J Korean Neurosurg Soc 27 : 53-58, 1998 |
19 | Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. : Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77 : 556-560, 2012 DOI |
20 | Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. : Brain metastases from lung cancer responding to erlotinib : the importance of EGFR mutation. Eur Respir J 37 : 624-631, 2011 DOI |
21 | Siegel R, Ma J, Zou Z, Jemal A : Cancer statistics, 2014. CA Cancer J Clin 64 : 9-29, 2014 DOI |
22 | Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 : 205-216, 2000 DOI |
23 | Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N, et al. : Radiotherapeutic management of brain metastases : a systematic review and meta-analysis. Cancer Treat Rev 31 : 256-273, 2005 DOI |
24 | Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. : Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31 : 895-902, 2013 DOI |
25 | Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. : Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 : 6829-6837, 2005 DOI |
26 | Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, et al. : Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75 : 82-88, 2012 DOI |
27 | Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. : Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol 11 : 121-128, 2010 DOI |